How Iron Works: Mechanisms of Action in the Body

How Iron Works: Mechanisms of Action

1. Executive Mechanism Summary
Iron works by being a reliable electron and oxygen handler. Its atom can sit at the center of a protein, bind oxygen or pass an electron on, and then return to its starting state. Evolution built an enormous part of animal biochemistry around that ability. Hemoglobin uses iron to carry oxygen, mitochondria use it to make ATP, and enzymes use it to copy DNA, make neurotransmitters and sense oxygen levels.
The same chemistry makes free iron dangerous, so the body controls it tightly. Iron is carried on transferrin, stored in ferritin, built into heme or iron-sulfur clusters, and kept out of reach of the hydrogen peroxide that would turn it into a source of damaging radicals. Because the body cannot excrete iron in a regulated way, the main control point is absorption, governed by a liver hormone called hepcidin.
In summary, iron appears to work through five linked mechanisms:
•    Oxygen transport and storage through heme in hemoglobin and myoglobin.
•    Energy production through iron-sulfur proteins and cytochromes in mitochondria.
•    DNA synthesis and repair through iron-dependent enzymes such as ribonucleotide reductase.
•    Cell signaling and oxygen sensing through iron-dependent hydroxylases and iron-sensing proteins.
•    Neurotransmitter and hormone synthesis through iron-containing hydroxylases and heme enzymes.
When iron is low, all five slow down at once, which helps explain why deficiency can cause fatigue, poor concentration and reduced exercise capacity. When iron is excessive, the same chemistry can drive oxidative injury. This guide explains each mechanism, separates what is well established from what is still hypothesized, and shows where human evidence supports the biology.
2. Key Active Compounds
Iron acts through the molecules that contain, carry or regulate it. A mineral does not have "active constituents" in the herbal sense, so the relevant compounds are iron forms and iron-handling proteins.
•    Ferrous iron (Fe2+): the soluble form that crosses membranes and enters most enzymes.
•    Ferric iron (Fe3+): the form that binds transferrin and is stored in ferritin. Most dietary non-heme iron is ferric.
•    Heme: an iron atom inside a protoporphyrin ring. It is the working part of hemoglobin, myoglobin, cytochromes, catalase and cytochrome P450 enzymes.
•    Iron-sulfur clusters: small clusters of iron and sulfur atoms that serve as electron carriers and catalytic centers.
•    Transferrin: a blood protein that binds two ferric iron atoms and delivers them to cells.
•    Ferritin: a hollow protein shell that stores iron safely in a mineral core.
•    Hepcidin: a small liver hormone that blocks iron release from cells.
•    Ferroportin: the only known cellular iron exporter in vertebrates.
•    Lactoferrin: an iron-binding protein in milk, tears and white blood cells that limits free iron for microbes.
Supplements deliver iron in several forms, but once absorbed they enter the same body pools, so the biology below applies to all of them.
3. Primary Biological Targets
Iron does not bind a single receptor the way a drug does. Its targets are the proteins and pathways that need it as a cofactor, and the sensors that detect it.
Red blood cell precursors in bone marrow. Developing red cells are the largest consumers of iron, taking up roughly 20–25 mg per day. They use it to make heme and hemoglobin.
Mitochondria. Complexes I, II and III of the respiratory chain contain iron-sulfur clusters, and cytochromes use heme. Mitochondria also assemble iron-sulfur clusters for the rest of the cell and are where heme is finished.
Brain. Iron is needed for myelin formation and for the enzymes that make dopamine and serotonin.
Proliferating cells. Immune cells, gut lining cells and bone marrow cells divide rapidly and need iron for ribonucleotide reductase.
The liver. It stores iron as ferritin and produces hepcidin, the system's master controller.
Macrophages. These cells engulf aging red blood cells and recycle their iron, which supplies most of the body's daily iron.
Regulatory sensors. Iron regulatory proteins, the oxygen-sensing HIF system and the BMP-SMAD pathway in the liver detect iron status and adjust the system.
4. Pathway 1: Absorption, Transport and Hepcidin Control
Absorption in the gut
Most iron is absorbed in the duodenum and upper jejunum. Dietary non-heme iron is mostly ferric, so it is reduced to ferrous iron by the enzyme duodenal cytochrome B and by dietary reducing agents such as vitamin C. Ferrous iron then crosses the brush border through divalent metal transporter 1, which is driven by the acidic environment next to the gut wall. Heme iron enters by a separate route that is not fully mapped. Inside the cell, heme oxygenase frees the iron.
Within the enterocyte, iron can go two ways. It can be stored in ferritin and lost when the cell sheds after a few days, or it can be exported through ferroportin on the blood side. Hephaestin, a copper-containing enzyme, then oxidizes it so that transferrin can pick it up.
Transport and uptake
Transferrin carries iron through the blood. Cells take it up when transferrin binds transferrin receptor 1 and the complex is drawn inside in a vesicle. The vesicle becomes acidic, iron is released and reduced, and it passes into the cytoplasm through DMT1. Transferrin and its receptor recycle back out. A small cytoplasmic "labile" pool is shared out by chaperone proteins to ferritin, to mitochondria or to enzymes.
Hepcidin and ferroportin
The key control step is the hepcidin–ferroportin axis. Hepcidin is made by liver cells and binds ferroportin, blocking its channel and marking it for internalization and degradation. When hepcidin is high, iron stays trapped in gut cells, macrophages and liver cells, and absorption falls. When hepcidin is low, iron flows out and into blood.
Hepcidin goes up with high iron stores, through the BMP-SMAD pathway involving the proteins HFE, transferrin receptor 2 and hemojuvelin, and with inflammation, through interleukin-6. It goes down with iron deficiency, low oxygen and increased red cell production, partly through the hormone erythroferrone, which is released by developing red cells. Defects at any of these points explain inherited conditions: too little hepcidin causes hemochromatosis, while too much hepcidin activity, as in TMPRSS6 mutations, causes iron-refractory anemia.
Dose effects
A dose of oral iron raises hepcidin within hours and the effect can last up to about a day. This is the leading mechanistic explanation for why large or repeated doses show diminishing returns, and why alternate-day dosing can raise the fraction of iron absorbed.
5. Pathway 2: Oxygen Transport and Storage
Heme synthesis
Inside developing red cells and in the liver, iron is inserted into protoporphyrin IX by the mitochondrial enzyme ferrochelatase, forming heme. Iron availability feeds back on this process: in red cell precursors, the first enzyme of heme synthesis is controlled by an iron-responsive element, so when iron is scarce, heme production slows. This is why low iron leads to small, pale red cells and to a rise in zinc protoporphyrin, which fills the heme ring in place of iron.
Hemoglobin
Hemoglobin is a protein made of four chains, each holding one heme. The iron at the center binds oxygen in the lungs, where oxygen is plentiful, and releases it in tissues, where oxygen is scarce. Each red cell carries hundreds of millions of hemoglobin molecules, and about two thirds of the body's iron lives here. The iron does not change its charge permanently when it binds oxygen. It remains ferrous, and its binding changes with the shape of the protein, which allows cooperative loading and unloading.
Myoglobin
Myoglobin has one heme and sits inside muscle cells. It binds oxygen more tightly than hemoglobin, which lets it store oxygen and hand it to mitochondria during exertion. This is one reason iron deficiency can limit exercise capacity even before anemia appears.
6. Pathway 3+: Energy Metabolism, DNA Synthesis and Iron-Dependent Enzymes
Mitochondrial energy production
Iron-sulfur clusters and heme are essential parts of the electron transport chain. Complexes I, II and III contain iron-sulfur centers, and cytochromes b, c1, c and the cytochrome oxidase complex use heme. These carry electrons toward oxygen while pumping protons that drive ATP synthesis. The Krebs cycle enzyme aconitase also contains an iron-sulfur cluster. When iron is limited, electron transport and ATP production decrease, tissues shift toward less efficient metabolism, and lactate may rise during effort. Tissues with high energy needs, such as muscle, heart and brain, are most affected.
DNA synthesis and repair
Ribonucleotide reductase turns RNA building blocks into the DNA building blocks. Its small subunit contains a di-iron center that generates a radical needed for the reaction. Several DNA polymerases, helicases and repair enzymes also carry iron-sulfur clusters. Cells that divide quickly, such as red cell precursors, lymphocytes and gut lining cells, therefore depend heavily on iron, and chelating iron slows the cell cycle in laboratory models.
Dioxygenases and epigenetics
A large family of enzymes uses ferrous iron, oxygen and 2-oxoglutarate, often with vitamin C helping to keep iron reduced. These include collagen prolyl hydroxylases, which stabilize collagen; the HIF prolyl hydroxylases, which control oxygen sensing; TET enzymes, which modify DNA methylation; and JmjC enzymes, which remove methyl groups from histones. Iron supply can therefore influence gene regulation, although the size of this effect in humans is not well known.
7. Cellular Signaling
Iron regulatory proteins
Cells monitor iron through iron regulatory proteins 1 and 2, which bind hairpin structures called iron-responsive elements on messenger RNAs. When iron is low, they bind and change how the message is used. Binding at the start of the ferritin message blocks its translation, so less ferritin is made. Binding at the end of the transferrin receptor message stabilizes it, so more receptor is made. The result is that the cell takes up more iron and stores less. When iron is plentiful, the process reverses. The first enzyme of heme synthesis in red cells and several other proteins are controlled the same way.
Oxygen sensing through HIF
The HIF prolyl hydroxylases need iron, oxygen and 2-oxoglutarate. When these are available, HIF transcription factors are tagged for destruction. When oxygen or iron is low, hydroxylation falls and HIF accumulates. HIF-2 then turns on genes for erythropoietin in the kidney and for DMT1, duodenal cytochrome B and ferroportin in the gut. This links iron and oxygen supply to red cell production and iron absorption, and explains why iron deficiency can alter signaling even before hemoglobin falls.
BMP-SMAD and JAK-STAT signaling
In the liver, iron increases bone morphogenetic protein 6, which signals through SMAD proteins to switch on the hepcidin gene. Inflammation signals through interleukin-6 and STAT3 to do the same. These two inputs explain why hepcidin responds both to iron and to infection.
Ferritin turnover
Ferritin releases iron when a cargo receptor called NCOA4 directs it to autophagy and lysosomal degradation, a process called ferritinophagy. This provides iron on demand during red cell production and is also tied to a form of cell death discussed below.
8. Oxidative Stress Pathways
Why free iron is hazardous
Ferrous iron reacts with hydrogen peroxide in the Fenton reaction to produce the hydroxyl radical, one of the most reactive molecules in biology. Ferric iron can be reduced back and the cycle repeats. Radicals attack lipids, proteins and DNA. The body prevents this by keeping iron bound at nearly every step.
Protective systems
Ferritin stores iron in its ferric form, and its heavy chain has ferroxidase activity that converts ferrous iron on entry. Transferrin binds iron in blood. Catalase, glutathione peroxidases and peroxiredoxins remove peroxides. Chaperones deliver iron directly to destinations so little remains loose.
When protection is overwhelmed
If iron enters blood faster than transferrin can bind it, non-transferrin-bound iron appears. It is taken up by the liver, heart and pancreas, and is associated with tissue injury in iron-overload conditions. A single large oral dose can also produce a temporary rise in non-transferrin-bound iron in some people, which is one proposed contributor to gut irritation, though this is not fully settled.
Ferroptosis
Ferroptosis is a form of regulated cell death in which iron-dependent lipid peroxidation destroys cell membranes. It is held in check mainly by the enzyme glutathione peroxidase 4, which repairs oxidized lipids. Iron availability, ferritin breakdown and polyunsaturated fats in membranes all increase susceptibility. Ferroptosis has been demonstrated in cells and animals and is under study in neurodegeneration, kidney injury and cancer. Its role in everyday supplement use at normal doses has not been shown.
9. Inflammatory Pathways
Hepcidin as an acute-phase response
During infection or inflammation, interleukin-6 raises hepcidin within hours. Iron then moves out of the blood into macrophages and cells, and serum iron falls. This is an ancient defense, sometimes called nutritional immunity, because many microbes need iron to grow. Lactoferrin, lipocalin-2 and transferrin further limit free iron for pathogens. In chronic inflammation the same response leads to anemia of inflammation, in which iron stores can be normal or high but iron is not available for red cell production. Oral iron works poorly in this setting because high hepcidin blocks its absorption.
Iron in immune cells
Lymphocytes need iron to proliferate, and neutrophils and macrophages use heme-containing enzymes, including NADPH oxidase components and myeloperoxidase, to produce the oxidative burst that kills microbes. Iron deficiency impairs these functions in laboratory and human studies. Macrophage iron handling also appears to shape their behavior: pro-inflammatory macrophages tend to hold iron, while repair-type macrophages tend to release it, although this picture is simplified.
Iron, infection and the gut
Because pathogens compete for iron, high-dose iron in infection-prone settings may raise risk. Large trials in malaria-endemic areas showed more serious illness in children given iron without malaria protection, and studies in African infants suggest unabsorbed iron may shift the gut microbiome toward more pathogenic bacteria. These findings are an important reason why dose, setting and infection control matter.
10. Endocrine, Neurotransmitter and Metabolic Pathways
Neurotransmitters
Tyrosine hydroxylase, the rate-limiting enzyme for dopamine, noradrenaline and adrenaline, uses ferrous iron as a cofactor. Tryptophan hydroxylase, which makes serotonin, does as well. Animal studies show that early iron deficiency changes dopamine signaling in the striatum and alters behavior, and this is the biological basis for hypotheses linking low iron to restless legs syndrome and attention problems. Direct proof of these links in people is limited.
Myelination and brain development
Oligodendrocytes, the cells that make myelin, contain high levels of iron and need it for lipid and cholesterol production. Iron deficiency in infancy has been linked to delayed myelination in animals and to lasting cognitive effects in some human studies.
Thyroid and other hormones
Thyroid peroxidase, which builds thyroid hormones, is a heme enzyme, and iron deficiency reduces its activity. Poor iron status can therefore blunt thyroid hormone production, and iodine supplementation works less well in iron-deficient children. Iron-containing cytochrome enzymes are also needed for steroid hormone synthesis.
Glucose and energy metabolism
Iron overload damages pancreatic beta cells and the liver, and diabetes is a known complication of severe hemochromatosis. Iron also affects insulin signaling and fat tissue in laboratory studies. Deficiency may limit thermogenesis and skeletal muscle oxidative capacity. Whether ordinary variations in iron status have meaningful effects on glucose control in people remains uncertain.
11. Mechanism Diagram
The diagram below shows the flow of iron from food to function, and where hepcidin acts. Described in words: dietary iron is absorbed by gut cells, exported by ferroportin into the blood, carried by transferrin to the bone marrow, muscle, brain and other tissues, and stored in the liver as ferritin. Macrophages recycle iron from old red cells. Hepcidin from the liver blocks ferroportin, and so controls how much iron enters the blood.
 
12. Preclinical Evidence
The mechanisms above come largely from cell and animal work, supplemented by human genetics.
•    Genetic models: mice lacking hepcidin develop severe iron overload, while mice that overproduce it become iron-deficient and anemic. Mice without intestinal DMT1 or ferroportin cannot absorb iron normally.
•    Human genetics: mutations in HFE, hemojuvelin, hepcidin and transferrin receptor 2 cause hemochromatosis, while TMPRSS6 mutations cause iron-refractory iron deficiency anemia. These are natural experiments that confirm the hepcidin pathway in humans.
•    Structural studies: cryo-electron microscopy has shown how hepcidin binds and blocks ferroportin.
•    Neurodevelopment models: iron-deficient rodents and primates show altered brain iron, dopamine signaling and myelination.
•    Cell biology: iron chelation halts cell proliferation by inhibiting ribonucleotide reductase, and excess iron drives lipid peroxidation and ferroptosis, which is blocked by specific inhibitors.
Limits apply. Rodents handle iron differently from humans, experimental doses are often much higher than dietary doses, and cell culture lacks the whole-body regulation that dominates real physiology.
13. Human Relevance
Several mechanisms have been confirmed directly in people.
•    Hepcidin dosing effects: studies using iron isotopes in young women showed that iron doses raise hepcidin and reduce absorption of later doses, and that alternate-day dosing increased fractional absorption compared with consecutive days. Trials comparing hemoglobin and ferritin outcomes have been less consistent.
•    Anemia of inflammation: high hepcidin in inflammatory disease and chronic kidney disease explains poor oral iron response and the value of intravenous iron.
•    Inherited disorders: hemochromatosis and iron-refractory anemia show the hepcidin pathway at work.
•    Oxygen delivery: correcting anemia improves aerobic capacity, consistent with the hemoglobin and mitochondrial roles.
•    Heart failure: people with heart failure often have iron deficiency, and heart muscle can show low iron and impaired mitochondrial function. Intravenous iron improved symptoms and exercise capacity in trials, which fits the energy-metabolism mechanism, though the exact benefit pathway is still being studied.
•    Fatigue in non-anemic deficiency: some trials show less fatigue when low ferritin is corrected, consistent with muscle and brain energy roles, but the evidence is not as strong as for anemia.
•    Brain and behavior: iron-deficient infants show lasting differences in some outcomes, consistent with the animal work, although causation in individual children is hard to prove.
In people with normal iron status, extra iron does not improve these functions. Mechanisms operate within a range, and above it the benefit stops while risks of side effects and accumulation continue.
14. Mechanistic Uncertainty
Despite decades of work, several important questions remain open.
•    Heme uptake: the transporter that moves heme into gut cells is not clearly identified, and proposed candidates are disputed.
•    Exact hepcidin–ferroportin mechanics: structures show how hepcidin blocks ferroportin, but how much of the effect is blockade versus degradation in different tissues continues to be studied.
•    Non-anemic iron deficiency: it is not fully clear which tissues drive symptoms such as fatigue, or how low ferritin must be before function changes.
•    Brain iron: how iron crosses into the brain, how it is regulated there, and whether low or high brain iron causes or merely accompanies neurological conditions is unresolved. A trial of iron chelation in early Parkinson's disease worsened outcomes, which shows how complicated the relationship is.
•    Ferroptosis in humans: it is clear in laboratory systems, but its contribution to human disease, and any link to ordinary iron intake, is not established.
•    Gut microbiome: how unabsorbed iron changes gut bacteria, and whether this matters for health in different populations and with different iron forms, is unclear.
•    Individual variation: genetic differences in iron genes, inflammation, sex hormones and diet change how people respond, and predicting that response remains imperfect.
Treat mechanistic statements as models that are strongly supported in some areas, such as hepcidin control and heme function, and more tentative in others, such as epigenetic and neurological effects.
15. References
1. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721–1741.
2. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142:24–38.
3. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A red carpet for iron metabolism. Cell. 2017;168:344–361.
4. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093.
5. Billesbølle CB, Azumaya CM, Kretsch RC, et al. Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms. Nature. 2020;586:807–811.
6. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678–684.
7. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40:569–571.
8. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126:1981–1989.
9. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days. Lancet Haematol. 2017;4:e524–e533.
10. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–1072.
11. Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509:105–109.
12. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832–1843.
13. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021;397:233–248.
14. Nairz M, Weiss G. Iron in infection and immunity. Mol Aspects Med. 2020;75:100864.
15. Lozoff B. Early iron deficiency has brain and behavior effects consistent with dopaminergic dysfunction. J Nutr. 2011;141:740S–746S.
16. Zimmermann MB, Köhrle J. The impact of iron and selenium deficiencies on iodine and thyroid metabolism. Thyroid. 2002;12:867–878.
17. Melenovsky V, Petrak J, Mracek T, et al. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail. 2017;19:522–530.
18. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–2448.
19. Sazawal S, Black RE, Ramsan M, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting. Lancet. 2006;367:133–143.
20. Jaeggi T, Kortman GAM, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64:731–742.
21. Devos D, Labreuche J, Rascol O, et al. Trial of deferiprone in Parkinson's disease. N Engl J Med. 2022;387:2045–2055.
22. Hurrell R, Egli I. Iron bioavailability and dietary reference values. Am J Clin Nutr. 2010;91:1461S–1467S.